Oncolys BioPharma Inc. [4588.T]
TOKYO, Apr 23 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) received notification from the U.S.
Food and Drug Administration (FDA) that its tumor lysing virus OBP-301, used in combination therapy for unresectable gastric and esophageal cancer, has been granted fast track designation. Fast track designation expedites the review process for drugs addressing serious conditions without satisfactory treatments. It allows for more frequent meetings and communications with the FDA, enabling submission for approval prior to complete data collection.
OBP-301 was designated as an orphan drug in the United States in 2020. The FDA's recognition underscores the potential importance of OBP-301 as a significant treatment option for esophageal cancer in the U.S. This designation is expected to have no impact on Oncolys BioPharma’s fiscal year ending December 2026 performance.
🟢 Confidence: High AI-translated content.